NO841230L - Interferon og interferon-induserende forbindelser kombinert med tobakksprodukter - Google Patents

Interferon og interferon-induserende forbindelser kombinert med tobakksprodukter

Info

Publication number
NO841230L
NO841230L NO841230A NO841230A NO841230L NO 841230 L NO841230 L NO 841230L NO 841230 A NO841230 A NO 841230A NO 841230 A NO841230 A NO 841230A NO 841230 L NO841230 L NO 841230L
Authority
NO
Norway
Prior art keywords
interferon
product
cells
cigarette
cigarettes
Prior art date
Application number
NO841230A
Other languages
English (en)
Norwegian (no)
Inventor
William Alvin Carter
Original Assignee
William Alvin Carter
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by William Alvin Carter filed Critical William Alvin Carter
Publication of NO841230L publication Critical patent/NO841230L/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A—HUMAN NECESSITIES
    • A24—TOBACCO; CIGARS; CIGARETTES; SIMULATED SMOKING DEVICES; SMOKERS' REQUISITES
    • A24B—MANUFACTURE OR PREPARATION OF TOBACCO FOR SMOKING OR CHEWING; TOBACCO; SNUFF
    • A24B15/00—Chemical features or treatment of tobacco; Tobacco substitutes, e.g. in liquid form
    • A24B15/18—Treatment of tobacco products or tobacco substitutes
    • A24B15/28—Treatment of tobacco products or tobacco substitutes by chemical substances
    • A24B15/30—Treatment of tobacco products or tobacco substitutes by chemical substances by organic substances
    • A—HUMAN NECESSITIES
    • A24—TOBACCO; CIGARS; CIGARETTES; SIMULATED SMOKING DEVICES; SMOKERS' REQUISITES
    • A24D—CIGARS; CIGARETTES; TOBACCO SMOKE FILTERS; MOUTHPIECES OF CIGARS OR CIGARETTES; MANUFACTURE OF TOBACCO SMOKE FILTERS OR MOUTHPIECES
    • A24D1/00—Cigars; Cigarettes
    • A24D1/18—Selection of materials, other than tobacco, suitable for smoking
    • A—HUMAN NECESSITIES
    • A24—TOBACCO; CIGARS; CIGARETTES; SIMULATED SMOKING DEVICES; SMOKERS' REQUISITES
    • A24D—CIGARS; CIGARETTES; TOBACCO SMOKE FILTERS; MOUTHPIECES OF CIGARS OR CIGARETTES; MANUFACTURE OF TOBACCO SMOKE FILTERS OR MOUTHPIECES
    • A24D3/00—Tobacco smoke filters, e.g. filter tips or filtering inserts; Filters specially adapted for simulated smoking devices; Mouthpieces of cigars or cigarettes
    • A24D3/06—Use of materials for tobacco smoke filters
    • A24D3/14—Use of materials for tobacco smoke filters of organic materials as additive
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/21—Interferons [IFN]

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Toxicology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Materials Engineering (AREA)
  • Pulmonology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Manufacture Of Tobacco Products (AREA)
  • Agricultural Chemicals And Associated Chemicals (AREA)
NO841230A 1982-08-05 1984-03-28 Interferon og interferon-induserende forbindelser kombinert med tobakksprodukter NO841230L (no)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US06/386,447 US4498485A (en) 1982-08-05 1982-08-05 Interferon and interferon inducers combined with tobacco products

Publications (1)

Publication Number Publication Date
NO841230L true NO841230L (no) 1984-03-28

Family

ID=23525614

Family Applications (1)

Application Number Title Priority Date Filing Date
NO841230A NO841230L (no) 1982-08-05 1984-03-28 Interferon og interferon-induserende forbindelser kombinert med tobakksprodukter

Country Status (12)

Country Link
US (1) US4498485A (de)
EP (1) EP0116085B1 (de)
JP (1) JPS59501496A (de)
AT (1) ATE28393T1 (de)
AU (1) AU561750B2 (de)
DE (1) DE3372568D1 (de)
DK (1) DK161738C (de)
FI (1) FI76246C (de)
IT (1) IT1168956B (de)
NO (1) NO841230L (de)
WO (1) WO1984000477A1 (de)
ZA (1) ZA835726B (de)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5394869A (en) * 1990-11-23 1995-03-07 Covarrubias; Jesus Method of inhibiting bronchospasms using taurine in an air filter
FR2696080B1 (fr) * 1992-09-30 1994-12-23 Jesus Covarrubias Filtre à cigarette pour l'administration de taurine par inhalation.
GB2332359B (en) * 1997-12-22 2001-10-24 Richard Graham Kendall Administration of a vitamin preparation to smokers via the filter tip of a cigarette
FR2798302B1 (fr) * 1999-09-13 2001-12-21 Frederic Maillard Filtre compose d'heterocycles azotes tels que l'adn destine notamment a la filtration de fumee de tabac, cigarette comportant un tel filtre

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2890973A (en) * 1954-03-03 1959-06-16 Fachini Giuseppe Treating tobacco and cigarette paper
US3339558A (en) * 1966-10-28 1967-09-05 Haskett Barry F Smoking article and filter therefor containing vitamin a
US3667478A (en) * 1969-07-17 1972-06-06 Nelson J Waterbury Filter cigarette incorporating vitamin a
EP0003064A3 (de) * 1977-12-07 1979-08-08 Rabam Limited Verfahren zum Einführen von Vitamin A-Analogen in die Atemwege eines Zigarettenrauchers
JPS5579319A (en) * 1978-12-07 1980-06-14 Shiyaaman Baaton Method of introducing vitamine a analogue to respiratory tract of smoker

Also Published As

Publication number Publication date
EP0116085A1 (de) 1984-08-22
FI841308L (fi) 1984-04-02
JPH0543347B2 (de) 1993-07-01
JPS59501496A (ja) 1984-08-23
DE3372568D1 (en) 1987-08-27
ZA835726B (en) 1984-12-24
IT8322461A0 (it) 1983-08-05
US4498485A (en) 1985-02-12
EP0116085A4 (de) 1984-11-16
AU561750B2 (en) 1987-05-14
IT1168956B (it) 1987-05-20
FI841308A0 (fi) 1984-04-02
WO1984000477A1 (en) 1984-02-16
EP0116085B1 (de) 1987-07-22
AU1885883A (en) 1984-02-23
DK179384D0 (da) 1984-04-05
ATE28393T1 (de) 1987-08-15
FI76246B (fi) 1988-06-30
DK179384A (da) 1984-04-05
DK161738B (da) 1991-08-12
DK161738C (da) 1992-02-24
FI76246C (fi) 1988-10-10

Similar Documents

Publication Publication Date Title
Hiemstra et al. The innate immune function of airway epithelial cells in inflammatory lung disease
Foster et al. Are all type I human interferons equivalent?
HÅKANssoN et al. Apoptosis induced by a human milk protein.
Stegelmeier et al. Type I interferon-mediated regulation of antiviral capabilities of neutrophils
JP2012529440A (ja) 病原体感染を予防又は治療するためのインターフェロン投与
SG191287A1 (en) Antimicrobial fusion compounds and uses thereof
JP2020519673A5 (de)
Sheshe et al. Mechanism of antiviral immune response and COVID-19 infection
Lai et al. Operation of mitochondrial machinery in viral infection-induced immune responses
Wen et al. Current progress on innate immune evasion mediated by Npro protein of pestiviruses
EP0116085B1 (de) Interferon und interferoninduzierer kombiniert mit tabakerzeugnissen
CN113425832A (zh) 干扰素λ在新型冠状病毒(2019-nCoV)感染治疗中的应用
Naito et al. Therapeutic potential of carbon monoxide (CO) for intestinal inflammation
NL8320256A (nl) Breed spectrum platenbescherming tegen pathogenen.
RU2526799C2 (ru) Фармацевтическая композиция и способ получения противовирусных фракций (антивирус-с)
KR20240128025A (ko) 치료용 i형 콜라겐 펩티드
CN111166741B (zh) Egcg在自身免疫疾病中的应用
Barathiraja et al. Natural killer (NK) cells: an innate defense shield against respiratory viral infections
Purbomartono et al. Non Specific Immune Potentiating Evaluation of Brown Seaweed of Padina sp. in Catfish and Pangasius
Polcyn-Adamczak et al. Cathelicidin–Its Structure, Function and the Role in Autoimmune Diseases
Wust A Hypothesis Expanded: Role of Ascorbate and Glucose in the Pathophysiology of Ebola Haemorrhagic Fever Considering Intracellular Factors and Viral Proteins Apart from the Envelope Glycoprotein
Daino Characterization of Ebola virus VP35-dsRNA binding for drug development against Ebola virus disease.
Priyadarsini et al. Role of trace element selenium in fighting COVID-19: are we ignoring this important element?
RU2380405C2 (ru) Способ получения рекомбинантного альфа 16-интерферона человека и фармацевтическая композиция для лечения вирусных заболеваний на основе рекомбинантного альфа 16-интерферона человека
ATASOY et al. Leptin does not act on proliferation but increases the expression of cell immunity-related genes MX-1, MX-2, and IFI-27 in the glioblastoma cell line T98G. Does leptin protect the cell from a viral intruder?